Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms

NCT05066373 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Disintegration
Healthy

Interventions

DRUG: EDP1815 capsule A
DRUG: EDP1815 capsule B
DRUG: EDP1815 tablet

Sponsor

Evelo Biosciences, Inc.